Clinical Study of Tirofiban in the Treatment of Different Sites of Progressive Ischemic Stroke
Objective:To explore the clinical effect of Tirofiban in the treatment of different sites of progressive ischemic stroke(PIS).Method:A total of 90 patients with PIS admitted to Shangrao People's Hospital from January 2023 to January 2024 were selected and divided into anterior circulation group(n=47)and posterior circulation group(n=50)according to different infarct sites.Both groups were given basic treatment+Tirofiban treatment.Platelet parameters,neurological deficit degree,clinical efficacy and adverse events were compared between the two groups.Result:After 1 week of treatment,platelet distribution width(PDW)and mean platelet volume(MPV)decreased in both groups,and platelet count(PLT)increased,PDW and MPV in posterior circulation group were smaller than those in anterior circulation group,and PLT was higher than that in anterior circulation group,the differences were statistically significant(P<0.05).At admission,there was no significant difference in national institutes of health stroke scale(NIHSS)scores between the two groups(P>0.05).After 2 days and 1 week of treatment,the NIHSS scores of posterior circulation group were lower than those of anterior circulation group,the differences were statistically significant(P<0.05).The total effective rate of posterior circulation group(86.00%)was higher than that in anterior circulation group(68.09%),the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse events between posterior circulation group(8.00%)and anterior circulation group(14.89%)(P>0.05).Conclusion:Tirofiban is effective in the treatment of PIS,and can effectively improve the platelet parameters and nerve function of patients,and it can improve the condition of patients with posterior circulation infarction more significantly,and has higher safety.
万方数据
维普
